Interventional × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Tacrolimus × Clear all
NCT04904588 2026-03-18

ACCESS

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
300 enrolled
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
NCT05031897 2025-10-30

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

Phase 2 Recruiting
63 enrolled
NCT03670966 2025-10-16

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled
NCT03779854 2025-10-15

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Recruiting
68 enrolled
NCT02790515 2025-08-12

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
170 enrolled
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Columbia University

Phase 1/2 Active not recruiting
14 enrolled
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT03096782 2023-10-11

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 10 charts
NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT00423514 2022-12-27

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
38 enrolled 12 charts
NCT01384513 2022-11-17

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled
NCT02129582 2021-05-07

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts